Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.

MLA

Stupp, R., et al. “Sagopilone (ZK-EPO, ZK 219477) for Recurrent Glioblastoma. A Phase II Multicenter Trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 22, no. 9, Sept. 2011, pp. 2144–49. EBSCOhost, https://doi.org/10.1093/annonc/mdq729.

APA

Stupp, R., Tosoni, A., Bromberg, J. E. C., Hau, P., Campone, M., Gijtenbeek, J., Frenay, M., Breimer, L., Wiesinger, H., Allgeier, A., van den Bent, M. J., Bogdahn, U., van der Graaf, W., Yun, H. J., Gorlia, T., Lacombe, D., & Brandes, A. A. (2011). Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 22(9), 2144–2149. https://doi.org/10.1093/annonc/mdq729

Chicago

Stupp, R, A Tosoni, J E C Bromberg, P Hau, M Campone, J Gijtenbeek, M Frenay, et al. 2011. “Sagopilone (ZK-EPO, ZK 219477) for Recurrent Glioblastoma. A Phase II Multicenter Trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 22 (9): 2144–49. doi:10.1093/annonc/mdq729.